Preexisting Mutations in the Rilpivirine Phase III Trials ECHO and THRIVE: Prevalence and Impact on Virologic Response

Antiviral Therapy - United Kingdom
doi 10.3851/imp2358
Full Text
Abstract

Available in full text

Date
Authors
Publisher

International Medical Press

Related search

Outcomes in Older Versus Younger Patients Over 96 Weeks in HIV-1– Infected Patients Treated With Rilpivirine or Efavirenz in ECHO and THRIVE

Current HIV Research
VirologyInfectious Diseases
2014English

Long-Term Clinical, Immunologic and Virologic Impact of Glucocorticoids on the Chronic Phase of HIV Infection

BMC Medicine
Medicine
2004English

Impact-Echo Response of Plates Containing Thin Layers and Voids

NDT and E International
Materials ScienceCondensed Matter PhysicsMechanical Engineering
1996English

Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Methodological Quality and Reporting of Ethical Requirements in Phase III Cancer Trials

Journal of Medical Ethics
ArtsHumanitiesLegal AspectsHealth PolicyHealthEthicsIssues
2005English

Impact of Safety Monitoring on Error Probabilities of Binary Efficacy Outcome Analyses in Large Phase III Group Sequential Trials

Pharmaceutical Statistics
StatisticsProbabilityPharmacology
2012English

Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients Without Advanced Liver Disease

Hepatology
MedicineHepatology
2018English

Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept

Clinical Cancer Research
Cancer ResearchOncology
2013English

Assessing the Impact of Safety Monitoring on the Efficacy Analysis in Large Phase III Group Sequential Trials With Non-Trivial Safety Event Rate

Journal of Biopharmaceutical Statistics
StatisticsProbabilityPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy